News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
701,368 Results
Type
Article (42888)
Company Profile (233)
Press Release (658247)
Section
Business (210941)
Career Advice (2129)
Deals (36999)
Drug Delivery (91)
Drug Development (83558)
Employer Resources (172)
FDA (16434)
Job Trends (15476)
News (357274)
Policy (34266)
Tag
Academia (2602)
Africa (798)
Allergies (40)
Alliances (51486)
Alzheimer's disease (1121)
Antibody-drug conjugate (ADC) (54)
Approvals (16372)
Arizona (167)
Artificial intelligence (60)
Asia (40398)
Australia (6382)
Bankruptcy (366)
Best Places to Work (11372)
Biosimilars (61)
C2C Services and Suppliers (80017)
California (827)
Canada (647)
Cancer (193)
Career advice (1774)
CAR-T (38)
Cell therapy (71)
China (50)
Clinical research (64973)
Collaboration (62)
Colorado (34)
COVID-19 (2545)
Cystic fibrosis (71)
Diabetes (35)
Diagnostics (5998)
Diversity, equity & inclusion (45)
Drug pricing (59)
Earnings (84857)
Employer resources (146)
Europe (86128)
Events (110897)
FDA (16479)
Florida (106)
Funding (39)
Gene therapy (61)
GLP-1 (522)
Government (4452)
Healthcare (18848)
Hotbed/Location (492389)
Idaho (55)
Illinois (201)
Indiana (108)
Infectious disease (2560)
Inflammatory bowel disease (88)
Interviews (334)
IPO (16548)
Job creations (4148)
Job search strategy (1542)
Kansas (90)
Layoffs (406)
Legal (8415)
Liver cancer (52)
Lung cancer (43)
Maine (47)
Management (55)
Manufacturing (52)
Maryland (255)
Massachusetts (456)
Medical device (13078)
Medtech (13081)
Mergers & acquisitions (20135)
Metabolic disorders (182)
Neuroscience (1206)
New Jersey (62)
New York (83)
NextGen Class of 2024 (6657)
Non-profit (4514)
North Carolina (167)
Obesity (119)
Opinion (199)
Parkinson's disease (30)
Patents (37)
Peanut (36)
Pennsylvania (55)
People (57985)
Phase I (20160)
Phase II (28556)
Phase III (21453)
Podcasts (55)
Policy (38)
Postmarket research (2663)
Preclinical (8548)
Rare diseases (93)
Real estate (6334)
Recruiting (65)
Regulatory (22157)
Reports (32)
Research institute (2370)
Resumes & cover letters (364)
South America (1173)
Startups (3765)
Texas (89)
United States (3051)
Vaccines (433)
Washington State (114)
Weight loss (120)
Date
Today (71)
Last 7 days (503)
Last 30 days (1957)
Last 365 days (39222)
2024 (22187)
2023 (40928)
2022 (52114)
2021 (56677)
2020 (55113)
2019 (47826)
2018 (36141)
2017 (33572)
2016 (33169)
2015 (39011)
2014 (32960)
2013 (28078)
2012 (30165)
2011 (30871)
2010 (28889)
701,368 Results for "ascendis pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Ascendis Pharma Reports First Quarter 2024 Financial Results
Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
May 2, 2024
·
12 min read
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 8:00 a.m. ET in Miami, Florida.
June 4, 2024
·
3 min read
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
Ascendis Pharma A/S reported new and updated results from its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ in a poster presentation at ASCO 2024, the annual meeting of the American Society of Clinical Oncology being held in Chicago May 31–June 4, 2024.
June 3, 2024
·
7 min read
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food and Drug Administration (FDA) notified the Company that information submitted in response to the FDA’s ongoing review of the New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism constituted a major amendment to the NDA.
May 14, 2024
·
4 min read
Business
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2024 financial results and provide a business update on Thursday, May 2, 2024, after the close of the U.S. financial markets.
April 25, 2024
·
3 min read
Ascendis Pharma Introduces Vision 2030
Ascendis Pharma A/S introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030.
January 7, 2024
·
9 min read
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024 at 2:00 p.m. ET in Miami, Florida.
March 4, 2024
·
3 min read
Business
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
February 7, 2024
·
13 min read
Policy
FDA Delays Review by Three Months for Ascendis’ Hypoparathyroidism Therapy
Following an initial rejection in 2023, Ascendis Pharma on Tuesday said it faces another regulatory bump in the road for TransCon PTH with a three-month delay in the ongoing FDA review.
May 15, 2024
·
2 min read
·
Tristan Manalac
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
February 7, 2024
·
3 min read
1 of 70,137
Next
